2025年In Vivo CAR-T竞争格局及BD情况：MNC重金布局，中国药企多点开花迎突破！

摩熵医药02-03

细胞治疗领域正迎来一场静水深流的变革。以CAR-T为代表的疗法虽已在血液肿瘤中展现出惊人疗效，但其高昂的成本与复杂的个性化制备流程，始终是横亘在患者面前的鸿沟。在此背景下，能在人体内直接“编辑”T细胞的In Vivo CAR-T技术，被视为破局的关键。2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608335603?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-03 11:43","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2608335603","market":"us","top_or_hot":-1,"title":"2025年In Vivo CAR-T竞争格局及BD情况：MNC重金布局，中国药企多点开花迎突破！","media":"摩熵医药","content":"<div>\n<p>细胞治疗领域正迎来一场静水深流的变革。以CAR-T为代表的疗法虽已在血液肿瘤中展现出惊人疗效，但其高昂的成本与复杂的个性化制备流程，始终是横亘在患者面前的鸿沟。在此背景下，能在人体内直接“编辑”T细胞的In Vivo CAR-T技术，被视为破局的关键。2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2025年In Vivo CAR-T竞争格局及BD情况：MNC重金布局，中国药企多点开花迎突破！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2025年In Vivo CAR-T竞争格局及BD情况：MNC重金布局，中国药企多点开花迎突破！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 11:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b><strong>摩熵医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>细胞治疗领域正迎来一场静水深流的变革。以CAR-T为代表的疗法虽已在血液肿瘤中展现出惊人疗效，但其高昂的成本与复杂的个性化制备流程，始终是横亘在患者面前的鸿沟。在此背景下，能在人体内直接“编辑”T细胞的In Vivo CAR-T技术，被视为破局的关键。2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1674673691.USD","symbol_name":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b","article_id":"2608335603","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203114341a475bdd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608335603","pubTimestamp":1770090193,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该技术路径的可行性。这不仅为自身免疫疾病的治疗开辟了新路径，也正式宣告In Vivo CAR-T从实验室加速走向临床应用。据不完全统计，仅2025年一年，全球围绕In Vivo CAR-T的重磅交易金额已超过65亿美元。2026年in vivo CAR-T赛道将持续火热，并且该趋势很有可能有增无减。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4534":"瑞士信贷持仓","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4504":"桥水持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","BK4550":"红杉资本持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","CAR":"安飞士","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0070217475.USD":"JPM GLOBAL SELECT EQUITY \"A\" ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4007":"制药","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","JNJ":"强生","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus"},"translate_title":"In Vivo CAR-T competitive landscape and BD situation in 2025: MNC has invested heavily in the layout, and Chinese pharmaceutical companies are blossoming in many places to welcome breakthroughs!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"JNJ":0.9},"content_text":"细胞治疗领域正迎来一场静水深流的变革。以CAR-T为代表的疗法虽已在血液肿瘤中展现出惊人疗效，但其高昂的成本与复杂的个性化制备流程，始终是横亘在患者面前的鸿沟。在此背景下，能在人体内直接“编辑”T细胞的In Vivo CAR-T技术，被视为破局的关键。2025年，这一前沿领域迎来了里程碑式的进展——虹信生物基于mRNA-LNP技术的In Vivo CAR-T候选药物HN2301首次在人体上验证了该技术路径的可行性。这不仅为自身免疫疾病的治疗开辟了新路径，也正式宣告In Vivo CAR-T从实验室加速走向临床应用。查数据，找摩熵！图源：摩熵医药数据库-全球药物研发数据库全球竞争格局，MNC巨头重金押注如果说In Vivo CAR-T在2023年还只是资本市场的概念热点，那么2024至2025年，则是跨国药企用真金白银下注加速卡位的关键窗口期。从公开的BD交易来看，这一趋势非常清晰迅猛。据不完全统计，仅2025年一年，全球围绕In Vivo CAR-T的重磅交易金额已超过65亿美元。其中，并购成为MNC快速获取核心技术的首选路径。阿斯利康以10亿美元收购EsoBiotec，看中的是其工程化纳米抗体慢病毒（ENABL）平台。艾伯维更是豪掷21亿美元拿下Capstan Therapeutics，旨在将其LNP递送技术收入囊中。紧随其后，BMS以15亿美元收购Orbital Therapeutics，吉利德/Kite则通过3.5亿美元收购Interius Bio Therapeutics及16.4亿美元授权普瑞金生物的在研管线，完成了在该领域的双重布局。这些密集的BD交易，不仅反映了MNC对In Vivo CAR-T颠覆性潜力的高度共识，也显示出其急于抢占先发优势的战略意图。除了直接收购也通过高价值的合作协议来探索多元技术。安斯泰来在2024年初便与Kelonia Therapeutics达成最高8.75亿美元的合作，共同开发基于慢病毒载体的体内CAR-T疗法。此后，诺华、强生也相继在2024年底和2025年底与Vyriad、Kelonia达成战略合作。这种“自研+外部引进”并行的模式，也已成为MNC布局前沿技术的方式。国内创新药企多点开花如果说全球MNC的密集布局代表了In Vivo CAR-T赛道的“顶层设计”，那么中国本土创新企业也代表了中国创新力量在快速跟进。从当前处于临床阶段的在研管线来看，国内企业在技术路径选择上呈现出多元化布局，且已有多项研究进入I/II期临床，展现出较强的自主研发能力。目前已有包括普瑞金生物（ESO-T01）、传奇生物（LVIVO-TaVec100）、嘉晨西海（JCXH-213）、济因生物（JY231）以及虹信生物（HN2301）在内的多家中国企业推进其In Vivo CAR-T产品进入临床试验阶段。虹信生物的进展尤为引人关注——其基于mRNA-LNP平台的HN2301，在2025年9月于《新英格兰医学杂志》发表的SLE患者临床数据，不仅是该技术路线在全球范围内的首次人体验证，也标志着中国企业在非病毒递送路径上实现了巨大的突破。图：虹信生物 在研管线此外，普瑞金生物与EsoBiotec合作开发的ESO-T01（靶向BCMA），已在多发性骨髓瘤及自身免疫疾病方向开展I期研究。传奇生物则利用其成熟的LNP递送平台，推进CD19/CD20双靶点疗法LVIVO-TaVec100的临床探索。而嘉晨西海、济因生物等企业也在血液肿瘤领域持续发力。值得注意的是，驯鹿医疗/Umoja Biopharma（由驯鹿医疗与Umoja合作）的UB-VV系列管线亦已进入I期临床，显示出国内企业在自免与血液瘤双线布局的意图。图：驯鹿医疗 在研管线这些管线的快速推进，离不开资本的持续支持。腾讯近年来在医疗领域的战略性投资，正是这一趋势的缩影。继布局圣因生物、跃赛生物、华毅乐健、圆因生物后，其入股虹信生物不仅延续了对核酸药物与细胞治疗前沿赛道的深耕，更体现了产业资本对In Vivo CAR-T技术成熟度与商业潜力的认可。总体而言，中国In Vivo CAR-T研发正从早期概念验证迈向临床验证阶段，技术路径覆盖病毒与非病毒两大方向，适应症拓展至血液瘤与自身免疫病。尽管仍面临递送效率、安全性长期随访等挑战，但以虹信生物为代表的本土创新力量，正在用真实世界的数据证明中国在下一代细胞治疗领域的竞争力。2026年in vivo CAR-T赛道将持续火热，并且该趋势很有可能有增无减。随着更多I期临床数据的披露以及II期关键实验的启动，行业也有望迎来从技术到临床价值的关键跃迁。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608335603","isCrawlerRequest":true}